Nico van Zandwijk
Nico van Zandwijk is an expert in Oncology at South Western Sydney Local Health District (Australia). As of October 2026, ScienceLeadR ranks Nico van Zandwijk in the top 1% of experts worldwide for Mesothelioma, Adenoma and Thoracic Neoplasms. Nico van Zandwijk has authored 428 publications, the most recent in 2026, and is an investigator in 2 clinical trials. SLR score: 1,366 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Pulmonology - Biochemistry - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1979 - 2026
Number : 428
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Environmental asbestos exposure and lung cancer burden compared with mesothelioma in rural Türkiye: A 33-Year population-based cohort study. PMID 42667889 — mortality, lung, mesothelioma, neoplasms, cohort studies, lung neoplasms, mesothelioma, malignant | Lung Cancer | 2026 | 0 |
| MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy. PMID 41898563 — cells, lung, drug tolerance, growth, micrornas, neoplasms, adenocarcinoma, multiple chronic conditions, carcinoma, non-small-cell lung, adenocarcinoma of lung, lung neoplasms, cell line, therapeutics | Int J Mol Sci | 2026 | 0 |
| Development of a history-taking form for mesothelioma patients at risk of exposure to asbestos. PMID 41376686 — diagnosis, differential, occupational health, mesothelioma, diagnosis, research, history | Public Health Action | 2025 | 0 |
| Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients. PMID 38956984 — cells, lung, neoplastic cells, circulating, neoplasms, drug therapy, lung neoplasms, small cell lung carcinoma, therapeutics, liquid biopsy, chemotherapy | Mol Oncol | 2024 | 2 |
| Therapeutic potential of synthetic microRNA mimics based on the miR-15/107 consensus sequence. PMID 40121357 — cells, growth, micrornas, neoplasms, carcinoma, non-small-cell lung, therapeutics, genetic therapy | Cancer Gene Ther | 2025 | 0 |
Clinical Studies 2
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
LeadR Networks
Main global connection map